NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

My suggested amalgamation of 2, 5, 8, and 12:-

When do you expect Sawston to be equipped, licensed, and operational?

To what extent will an operational Sawston allow for increased manufacture of DCVax treatments, prior to marketing authorisation, so that treatments can be provided to individual patients on reimbursed compassionate use programmes, such as the UK Specials scheme?

How many operating cleanrooms, and how many individual patient manufactures can be achieved per month in the pre-approval period, to service patients who have eligibility under a special programme?

Can you give us a projection on how many reimbursed treatments it is anticipated will be done at Sawston per month before approval, and to what extent this will be greater than the temporary manufacturing site in London?
And can you give an indication as to how this might translate into revenue for NWBO?

I've toned down any too obvious references to UK Specials, because I think they will be very wary of going in to depth on the issue, because they must not be seen to be promoting or publicising their supplying of UK Specials treatment in any way.
They do not want to jeopardise this method of treating patients and being reimbursed at all.
Understandably.
I've also started looking a bit deeper at UK Specials, and it's actually the case that many treatments under the scheme are funded by the NHS out of the public purse at least for UK citizens.
If this applied to DCVax-L, I could imagine the demand being may be 5 times higher than we previously anticipated.

I will report back on UK Specials again when I've had more a chance to delve deeper into the scheme.

Thanks Senti.